4/A//SEC Filing
Kim Na Yeon 4/A
Accession 0001104659-23-084928
CIK 0001638287other
Filed
Jul 27, 8:00 PM ET
Accepted
Jul 28, 6:02 AM ET
Size
6.3 KB
Accession
0001104659-23-084928
Insider Transaction Report
Form 4/AAmended
Kim Na Yeon
Director10% Owner
Transactions
- Other
Common Stock
2022-07-26+4,671→ 4,671 total(indirect: Held by E&Investment Inc.)
Footnotes (4)
- [F1]This amendment is being filed to add the acquisition of 4,671 shares by E&Investment Inc., which was inadvertently left off the original Form 4.
- [F2]E&Investment Inc. received a pro rata distribution from E&Healthcare Investment Fund II, of which the reporting person is a limited partner, for no consideration.
- [F3]The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock.
- [F4]Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.
Documents
Issuer
NeuroBo Pharmaceuticals, Inc.
CIK 0001638287
Entity typeother
Related Parties
1- filerCIK 0001794779
Filing Metadata
- Form type
- 4/A
- Filed
- Jul 27, 8:00 PM ET
- Accepted
- Jul 28, 6:02 AM ET
- Size
- 6.3 KB